admin – Page 4570 – Get News Story

A Comprehensive Guide to Forklift Battery Types Introduced by Redway Battery

In industrial operations, forklifts play a crucial role in material handling, and the batteries powering them are vital for ensuring efficiency, productivity, and cost-effectiveness. Selecting the appropriate forklift battery can significantly impact performance, reduce downtime, and optimize operational costs. Redway Battery, a leader in advanced lithium battery technology, recently has presented a detailed guide to forklift battery types to assist businesses in making well-informed decisions.

The Evolution of Forklift Batteries

The forklift battery market has evolved, offering a range of options to cater to diverse industrial needs. From traditional lead-acid batteries to modern lithium-ion (LiFePO4) solutions, each type offers distinct advantages and operational characteristics.

Primary Forklift Battery Types

1. Lead-Acid Batteries: A Time-Tested Solution

Lead-acid batteries, also known as wet-cell batteries, have been a mainstay in industrial applications for decades. These batteries utilize lead plates submerged in a sulfuric acid and water solution.

Lifespan: Typically lasts 1,000 to 1,500 cycles, equivalent to 3 to 5 years with proper maintenance.
Maintenance: Requires periodic watering to maintain electrolyte levels.
Advantages:
- Availability: Widely used and easily sourced across industries.
- Affordability: Features a lower upfront cost compared to newer battery technologies.

2. Lithium-Ion (LiFePO4) Batteries: The Modern Standard

Lithium-ion batteries are transforming the material handling industry with their superior performance and low maintenance requirements.

Lifespan: Lasts between 2,000 and 3,000 cycles, equating to 7 to 10 years of operation.
Maintenance: Maintenance-free and requires no watering.
Advantages:
- Fast Charging: Reduces downtime through rapid recharging capabilities.
- Safety and Durability: Sealed construction minimizes risks of spills or leaks.
- Eco-Friendly: Emits no harmful gases and has a lower environmental impact.

3. Absorbed Glass Mat (AGM) Batteries: A Spill-Proof Option

AGM batteries utilize a specialized glass mat to contain the electrolyte, making them spill-proof and maintenance-free.

Lifespan: Comparable to lead-acid batteries, with variations depending on usage.
Maintenance: Requires minimal upkeep.
Advantages:
- Safety: Eliminates the risk of spills.
- Convenience: Provides a user-friendly option for operations requiring lower maintenance.

4. Tubular Plate Batteries: Designed for High Demand

Tubular plate batteries are tailored for extended operating times and high-load applications.

Lifespan: Generally shorter than flat-plate alternatives.
Advantages:
- Extended Runtime: Suitable for heavy-duty operations requiring prolonged energy delivery.
- Voltage Efficiency: Handles higher voltage demands effectively.

5. Waterless Batteries: Simplifying Maintenance Efforts

Waterless batteries reduce the need for frequent electrolyte refills, offering a low-maintenance alternative for busy industrial environments.

Advantages:
- Reduced Labor: Requires less frequent maintenance, saving time and costs.
- Efficiency: Ideal for operations with limited personnel for maintenance tasks.

6. Thin Plate Pure Lead (TPPL) Batteries: A Cost-Effective Alternative

TPPL batteries provide some of the advantages of lithium-ion technology at a more affordable price point.

Advantages:
- Maintenance-Free: Does not require regular servicing.
- Cost-Effective: Balances performance and affordability.

Comparing Forklift Battery Options

Each type of forklift battery offers distinct characteristics, making it essential to evaluate operational requirements before making a selection:

Lead-Acid Batteries: Best suited for businesses focused on affordability, with resources for regular maintenance.
Lithium-Ion Batteries: Ideal for modern operations emphasizing efficiency, fast charging, and long lifespans.
AGM Batteries: Designed for environments requiring spill-proof and low-maintenance solutions.
Tubular Plate Batteries: Preferred for applications demanding extended runtime and high energy output.
Waterless Batteries: Tailored for operations aiming to minimize maintenance efforts.
TPPL Batteries: A practical choice for balancing cost and convenience.

The Benefits of Lithium-Ion (LiFePO4) Technology

Lithium-ion batteries, particularly those utilizing LiFePO4 technology, are gaining prominence due to their unmatched efficiency and eco-friendly attributes.

Key Advantages of LiFePO4 Batteries

Enhanced Energy Density: Delivers superior performance in a compact design.
Sustainability: Features recyclable components and emits no harmful gases.
Long-Term Savings: Higher initial investment is offset by reduced maintenance and extended operational life.

Factors to Consider When Selecting a Forklift Battery

Choosing the right forklift battery involves analyzing various operational parameters:

Energy Requirements: Evaluate the power demands and runtime needs of the equipment.
Maintenance Capabilities: Assess the ability to manage maintenance requirements, if any.
Budget Constraints: Consider both upfront costs and long-term operational savings.
Environmental Goals: Select technologies aligned with sustainability initiatives.

The Role of Redway Battery in Forklift Power Solutions

Redway Battery stands at the forefront of forklift battery innovation, offering high-quality lithium battery solutions designed for industrial applications.

Technological Expertise

Specializing in advanced LiFePO4 technology, Redway Battery delivers unmatched reliability, safety, and efficiency.

Custom Solutions

Redway Battery provides tailored lithium battery solutions to meet specific industrial requirements, ensuring optimal performance and compatibility.

Commitment to Sustainability

By prioritizing eco-friendly manufacturing processes, Redway Battery supports industrial sustainability efforts worldwide.

FAQs About Forklift Batteries

How long do forklift batteries typically last?

The lifespan varies by type. Lead-acid batteries last around 3 to 5 years, while lithium-ion batteries offer 7 to 10 years of service.

What makes lithium-ion batteries more efficient than lead-acid batteries?

Lithium-ion batteries provide longer lifespans, faster charging, and maintenance-free operation, resulting in greater overall efficiency.

Are lithium batteries compatible with all forklifts?

Compatibility depends on the forklift model. It is essential to verify specifications before transitioning to lithium batteries.

Conclusion

Understanding the types of forklift batteries and their respective benefits is crucial for optimizing industrial operations. Traditional lead-acid batteries remain a reliable choice for cost-sensitive applications, while lithium-ion batteries are emerging as the preferred solution for their efficiency, longevity, and environmental advantages.

Redway Battery continues to lead the charge in forklift battery innovation, providing cutting-edge LiFePO4 solutions designed to enhance operational performance and sustainability in material handling equipment.

Media Contact
Company Name: Redway Battery Tech
Contact Person: Mr. Smith
Email: Send Email
Country: United States
Website: https://www.redway-tech.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: A Comprehensive Guide to Forklift Battery Types Introduced by Redway Battery

Spinal Muscular Atrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and MOA, ROA by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme Corp

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Spinal Muscular Atrophy pipeline constitutes 18+ key companies continuously working towards developing 20+ Spinal Muscular Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Spinal Muscular Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Spinal Muscular Atrophy Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Muscular Atrophy Market.

Some of the key takeaways from the Spinal Muscular Atrophy Pipeline Report:

Companies across the globe are diligently working toward developing novel Spinal Muscular Atrophy treatment therapies with a considerable amount of success over the years.
Spinal Muscular Atrophy companies working in the treatment market are Skyline Therapeutics, Exegenesis Bio, Biogen, GeneCradle Inc., Hangzhou Jiayin Biotech Ltd, Scholar Rock, Inc., Biohaven Pharmaceuticals, Inc, and others, are developing therapies for the Spinal Muscular Atrophy treatment

Emerging Spinal Muscular Atrophy therapies in the different phases of clinical trials are- SKG 0201, Spinal muscular atrophy gene therapy, BIIB115, GC101, EXG001-307, Apitegromab, Talditercept alfa, and others are expected to have a significant impact on the Spinal Muscular Atrophy market in the coming years.
In November 2024, Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative therapies for various rare and common diseases, announced updates on the development programs for taldefgrobep alfa in Spinal Muscular Atrophy (SMA) and obesity.
In November 2024, Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to developing innovative therapies for spinal muscular atrophy (SMA), cardiometabolic conditions, and other severe diseases driven by protein growth factors, has announced positive and statistically significant topline results from the pivotal Phase 3 SAPPHIRE trial. These findings highlight the potential of apitegromab to transform the standard of care for SMA patients.
In April 2024, Exegenesis Bio, a fast-expanding global leader in genetic medicine, has shared clinical efficacy and safety findings from its Phase 1/2 trial (EXG001-307) for Spinal Muscular Atrophy (SMA) Type I. The data was presented on May 8, 2024, during the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Baltimore, Maryland (poster #627).

Spinal Muscular Atrophy Overview

Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disorder characterized by the progressive degeneration of motor neurons in the spinal cord and brainstem. Motor neurons are nerve cells responsible for controlling voluntary muscle movement. When these motor neurons degenerate, muscles weaken and atrophy, leading to difficulties with movement, muscle weakness, and potentially life-threatening respiratory problems.

Get a Free Sample PDF Report to know more about Spinal Muscular Atrophy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/spinal-muscular-atrophy-sma-pipeline-insight

Emerging Spinal Muscular Atrophy Drugs Under Different Phases of Clinical Development Include:

SKG 0201: Skyline Therapeutics
Spinal muscular atrophy gene therapy: Exegenesis Bio
BIIB115: Biogen
GC101: GeneCradle Inc.
EXG001-307: Hangzhou Jiayin Biotech Ltd
Apitegromab: Scholar Rock, Inc.
Talditercept alfa: Biohaven Pharmaceuticals, Inc

Spinal Muscular Atrophy Route of Administration

Spinal Muscular Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Spinal Muscular Atrophy Molecule Type

Spinal Muscular Atrophy Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Spinal Muscular Atrophy Pipeline Therapeutics Assessment

Spinal Muscular Atrophy Assessment by Product Type
Spinal Muscular Atrophy By Stage and Product Type
Spinal Muscular Atrophy Assessment by Route of Administration
Spinal Muscular Atrophy By Stage and Route of Administration
Spinal Muscular Atrophy Assessment by Molecule Type
Spinal Muscular Atrophy by Stage and Molecule Type

DelveInsight’s Spinal Muscular Atrophy Report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Spinal Muscular Atrophy product details are provided in the report. Download the Spinal Muscular Atrophy pipeline report to learn more about the emerging Spinal Muscular Atrophy therapies

Some of the key companies in the Spinal Muscular Atrophy Therapeutics Market include:

Key companies developing therapies for Spinal Muscular Atrophy are – Genentech Inc, Chugai Pharmaceutical, Cytokinetics Inc., Ionis Pharmaceuticals Inc., Genzyme Corporation, Novartis International AG, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, PerkinElmer Inc., Pfizer Inc., UW Health, Novo Nordisk A/S, Cure SMA, Boehringer Ingelheim Gmbh, Biogen Inc, F. Hoffmann-La Roche AG, Catalyst Pharmaceutical, Salarius Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Isis Pharmaceuticals Inc., PTC Therapeutics, Natera Inc, AstraZeneca PLC, and others.

Spinal Muscular Atrophy Pipeline Analysis:

The Spinal Muscular Atrophy pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Spinal Muscular Atrophy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy Treatment.
Spinal Muscular Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Spinal Muscular Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Muscular Atrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Spinal Muscular Atrophy drugs and therapies

Spinal Muscular Atrophy Pipeline Market Drivers

Increase in prevalence of Spinal Muscular Atrophy, increasing number of clinical trials and government funding for R&D are some of the important factors that are fueling the Spinal Muscular Atrophy Market.

Spinal Muscular Atrophy Pipeline Market Barriers

However, lack of public knowledge of this rare medical condition, cost associated with the treatment and other factors are creating obstacles in the Spinal Muscular Atrophy Market growth.

Scope of Spinal Muscular Atrophy Pipeline Drug Insight

Coverage: Global
Key Spinal Muscular Atrophy Companies: Skyline Therapeutics, Exegenesis Bio, Biogen, GeneCradle Inc., Hangzhou Jiayin Biotech Ltd, Scholar Rock, Inc., Biohaven Pharmaceuticals, Inc, and others
Key Spinal Muscular Atrophy Therapies: SKG 0201, Spinal muscular atrophy gene therapy, BIIB115, GC101, EXG001-307, Apitegromab, Talditercept alfa, and others
Spinal Muscular Atrophy Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies
Spinal Muscular Atrophy Market Dynamics: Spinal Muscular Atrophy market drivers and Spinal Muscular Atrophy market barriers

Request for Sample PDF Report for Spinal Muscular Atrophy Pipeline Assessment and clinical trials

Table of Contents

1. Spinal Muscular Atrophy Report Introduction

2. Spinal Muscular Atrophy Executive Summary

3. Spinal Muscular Atrophy Overview

4. Spinal Muscular Atrophy- Analytical Perspective In-depth Commercial Assessment

5. Spinal Muscular Atrophy Pipeline Therapeutics

6. Spinal Muscular Atrophy Late Stage Products (Phase II/III)

7. Spinal Muscular Atrophy Mid Stage Products (Phase II)

8. Spinal Muscular Atrophy Early Stage Products (Phase I)

9. Spinal Muscular Atrophy Preclinical Stage Products

10. Spinal Muscular Atrophy Therapeutics Assessment

11. Spinal Muscular Atrophy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Spinal Muscular Atrophy Key Companies

14. Spinal Muscular Atrophy Key Products

15. Spinal Muscular Atrophy Unmet Needs

16 . Spinal Muscular Atrophy Market Drivers and Barriers

17. Spinal Muscular Atrophy Future Perspectives and Conclusion

18. Spinal Muscular Atrophy Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Spinal Muscular Atrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and MOA, ROA by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme Corp

Scleroderma Pipeline Analysis 2024: FDA Approvals and Emerging Therapies, by DelveInsight | Bayer, Novartis, GSK, Boehringer Ingelheim, Celgene Crp., Johnson & Johnson, Prometic Life Sciences

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Scleroderma pipeline constitutes 45+ key companies continuously working towards developing 50+ Scleroderma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Scleroderma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Scleroderma Market.

The Scleroderma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Scleroderma Pipeline Report:

Companies across the globe are diligently working toward developing novel Scleroderma treatment therapies with a considerable amount of success over the years.
Scleroderma companies working in the treatment market are Genentech, AnaMar AB, Acceleron Pharma, Boehringer Ingelheim, Vedotin Seagen, Horizon Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, and others, are developing therapies for the Scleroderma treatment

Emerging Scleroderma therapies in the different phases of clinical trials are- RO7303509, AM 1476, MK-2225, BI 685509, Brentuximab, HZN-825, MT-0551, and others are expected to have a significant impact on the Scleroderma market in the coming years.
In November 2024, Zura Bio Limited (Nasdaq: ZURA), a clinical-stage immunology company focused on developing innovative dual-pathway antibodies for autoimmune and inflammatory conditions, has submitted a protocol under its active Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). The protocol pertains to a Phase 2 study of tibulizumab, a humanized tetravalent bispecific dual antagonist antibody targeting both IL-17A and BAFF, intended for the treatment of systemic sclerosis (SSc) in adult patients.

Scleroderma Overview

Scleroderma is a chronic autoimmune disease that causes the hardening and thickening of the skin and connective tissues. It can also affect internal organs, blood vessels, and the immune system, leading to complications ranging from skin changes to organ dysfunction.

Get a Free Sample PDF Report to know more about Scleroderma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/scleroderma-pipeline-insight

Emerging Scleroderma Drugs Under Different Phases of Clinical Development Include:

RO7303509: Genentech
AM 1476: AnaMar AB
MK-2225: Acceleron Pharma
BI 685509: Boehringer Ingelheim
Brentuximab: Vedotin Seagen
HZN-825: Horizon Pharmaceuticals
MT-0551: Mitsubishi Tanabe PharmaCorporation

Scleroderma Route of Administration

Scleroderma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Scleroderma Molecule Type

Scleroderma Products have been categorized under various Molecule types, such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Scleroderma Pipeline Therapeutics Assessment

Scleroderma Assessment by Product Type
Scleroderma By Stage and Product Type
Scleroderma Assessment by Route of Administration
Scleroderma By Stage and Route of Administration
Scleroderma Assessment by Molecule Type
Scleroderma by Stage and Molecule Type

DelveInsight’s Scleroderma Report covers around 50+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Scleroderma product details are provided in the report. Download the Scleroderma pipeline report to learn more about the emerging Scleroderma therapies

Some of the key companies in the Scleroderma Therapeutics Market include:

Key companies developing therapies for Scleroderma are – Boehringer Ingelheim International GmbH, Celgene Corporation, Johnson & Johnson Services, Inc., Prometic Life Sciences Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals, Cytori Therapeutics Inc., Bayer AG, F. Hoffman La Roche Ltd, arGentis Pharmaceuticals LLC, GlaxoSmithKline PLC (GSK), Novartis AG, and others.

Scleroderma Pipeline Analysis:

The Scleroderma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Scleroderma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Scleroderma Treatment.
Scleroderma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Scleroderma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Scleroderma market.

Download Sample PDF Report to know more about Scleroderma drugs and therapies

Scleroderma Pipeline Market Drivers

Pharmaceutical and Biotechnology Industries striving on the development of new therapy, increased Awareness among people related to the disease are some of the important factors that are fueling the Scleroderma Market.

Scleroderma Pipeline Market Barriers

However, higher healthcare cost, adverse effects associated with the drugs and other factors are creating obstacles in the Scleroderma Market growth.

Scope of Scleroderma Pipeline Drug Insight

Coverage: Global
Key Scleroderma Companies: Genentech, AnaMar AB, Acceleron Pharma, Boehringer Ingelheim, Vedotin Seagen, Horizon Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, and others
Key Scleroderma Therapies: RO7303509, AM 1476, MK-2225, BI 685509, Brentuximab, HZN-825, MT-0551, and others
Scleroderma Therapeutic Assessment: Scleroderma current marketed and Scleroderma emerging therapies
Scleroderma Market Dynamics: Scleroderma market drivers and Scleroderma market barriers

Request for Sample PDF Report for Scleroderma Pipeline Assessment and clinical trials

Table of Contents

1. Scleroderma Report Introduction

2. Scleroderma Executive Summary

3. Scleroderma Overview

4. Scleroderma- Analytical Perspective In-depth Commercial Assessment

5. Scleroderma Pipeline Therapeutics

6. Scleroderma Late Stage Products (Phase II/III)

7. Scleroderma Mid Stage Products (Phase II)

8. Scleroderma Early Stage Products (Phase I)

9. Scleroderma Preclinical Stage Products

10. Scleroderma Therapeutics Assessment

11. Scleroderma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Scleroderma Key Companies

14. Scleroderma Key Products

15. Scleroderma Unmet Needs

16 . Scleroderma Market Drivers and Barriers

17. Scleroderma Future Perspectives and Conclusion

18. Scleroderma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Scleroderma Pipeline Analysis 2024: FDA Approvals and Emerging Therapies, by DelveInsight | Bayer, Novartis, GSK, Boehringer Ingelheim, Celgene Crp., Johnson & Johnson, Prometic Life Sciences

Houmanity Unlocks New Milestone, Driving Growth for Over 500 Orthodontic Practices

Irvine, CA – December 20, 2024 – Houmanity, a marketing solutions provider for orthodontic practices, has reached a key milestone in its journey – helping more than 500 practices achieve growth and success. This achievement reflects the company’s dedication to enhancing its clients’ online presence, improving client acquisition, and delivering tailored marketing solutions that drive measurable results.

This milestone is marked by significant growth metrics across its client base. With Houmanity’s support, orthodontic practices have created over 250,000 patient appointments, demonstrating the impact of targeted orthodontic marketing strategies on achieving business goals. On average, their clients have reported a 20x return on investment (ROI), with many practices experiencing up to 200% business growth.

A key driver in achieving this milestone is Houmanity’s expertise in improving Google rankings for its clients. Through targeted campaigns and SEO-driven approaches, the company has helped practices significantly boost website traffic and patient conversion rates. Additionally, Houmanity’s cohesive branding solutions help practices establish a strong and consistent online presence aligned with their unique values and goals.

Houmanity’s data-driven services integrate custom web design, branding, search engine optimization (SEO), Google Ads management, and even interior design. By addressing every aspect of marketing under one roof, Houmanity enables its clients to streamline their operations and focus on delivering quality patient care.

Beyond metrics, this milestone highlights the broader trend within the orthodontic industry, where practices increasingly rely on digital tools and strategies to remain competitive. Houmanity reflects this shift by providing practices with the support and tools needed to navigate the challenges of a digital-first environment.

Looking ahead, the company remains committed to developing innovative marketing solutions tailored to the evolving needs of orthodontic practices. Its mission remains the same: helping orthodontic practices thrive and creating meaningful patient experiences that drive sustainable growth.

For more information about Houmanity’s services or to schedule a consultation, please visit https://www.houmanity.com/.

About Houmanity

Since 2012, Houmanity has been at the forefront of delivering innovative marketing solutions for orthodontic and healthcare practices. Specializing in SEO, branding, custom web design, and Google Ads management, the company provides a comprehensive, data-driven approach to helping practices grow and succeed in a competitive digital landscape. Houmanity’s mission is to simplify marketing for its clients and enable them to focus on patient care.

Media Contact
Company Name: Houmanity
Contact Person: Houman Baik
Email: Send Email
Phone: (949)-656-5663
Country: United States
Website: https://www.houmanity.com/

Chez Les Mannequins Takes Art Basel to Mondrian South Beach

Painting courtesy of Amarildo Ruçi, Art Basel Miami, December 7, 2024

Where fashion and art collide, Chez Les Mannequins produces an eclectic event during Art Basel Miami for intriguing artists and fashion designers. Chez Les Mannequins is a high fashion and commercial creative agency based worldwide, producing and providing talent to clients ranging from Adidas, Reebok, New Balance, L’Oréal, Maybelline, Urban Decay, Vogue, Thayers, Kiehls, and more. This December, Chez Les Mannequins brought elegance to abstract and surreal painters in an event combining art, film, fashion, and humanitarianism.

The event program consisted of a cocktail party with complimentary drinks and hors d’oeuvres, a short film presentation, live painting performances, and an auction of items supporting charity. The intimate event organized by Karine Charlemagne, an International Political Economist, Urban Scientist, and Activist, is sure to be the first of many quality Art Basel Miami presentations.

THE ART

Amarildo Ruçi

Amarildo Ruçi: From Canvas to Couture

Amarildo Ruçi has made his mark on the international art scene through his unique blend of finger-painting and symbolic surrealism. His work has been showcased in some of the world’s most prestigious cities including Milan, Heidelberg, Madrid, New York, Cyprus, Turkey, Berlin, and Paris Louvre. Inspired by the demand of clients who wanted to carry his art into their daily lives, Amarildo ventured into fashion. He launched @amarildoshop on Instagram, transforming his paintings into wearable designs. The Amru Collection takes this concept to new heights, featuring designs that incorporate key elements of Amarildo’s paintings. These elements are reimagined and refined to create pieces that are as unique as they are artistic. The collection debuted at Art Basel Miami Beach, with models from Chez Le Mannequins showcasing this fusion of art and fashion. In addition to showcasing his fashion brand, Amarildo showcased some of his art work and even gave a live painting performance. Ruçi gave an emotional depiction of his journey as an artist through his art and words painting an eye in various transitioning environments. Amarildo’s mission is to merge art and fashion seamlessly, offering people a way to express themselves while celebrating contemporary art. His ultimate goal is to establish Amru as a globally recognized clothing brand, embodying creativity, individuality, and innovation. His success story reflects not only his artistic achievements but also his ability to innovate and adapt. As Amru Collection makes its debut on the global stage, Amarildo is already planning the next steps to expand his brand internationally, building on the strong foundation of his artistic legacy.

Amarildo Ruci

https://amarildoruci.myshopify.com/

rucii.amarildo@gmail.com

IG: @amarildoshop

IG:@amarildoruci

+1 (617)516-7577

LoveCashionista

LoveCashionista is a one of a kind brand based in Boston, MA that specializes in physical and digital art, fashion design, and photography. The brand started in the beginning of the pandemic where the first crochet item created was a headband to alleviate ear discomfort from masks. In the photo are LoveCashionista’s signature crochet hoop earrings, bracelet, and clutch handbag.

From then to now the brand has grown in many ways. The vividly expressive work has been recognized at a variety of exhibitions and featured in major publications worldwide.

The brand continuously works to develop, evolve and expand through its mission of finding beauty in the struggle, turning pain into power. The goal is to be an inspiration and advocate for women, minorities, and low-income communities. During Art Basel Miami, LoveCashionista showcased fashion accessories from their holiday collection, original artwork and did a live abstract Miami inspired painting. In the future, the brand is working on many new, exciting projects that include television and digital media. Ultimately, LoveCashionista envisions creating a collection that provides opportunities to help and support other upcoming artists.

Briana Lee

www.lovecashfashion.com

lovecashionista@gmail.com

IG: @LoveCashionista

+1 (617)251-2035

THE FASHION

Fioletowy

Fioletowy, founded in 2017, aims to fuse global elegance with purpose. This brand’s creations draw inspiration from faith, art, and diverse cultures, blending European refinement, Japanese minimalism, and Indian craftsmanship.

Fioletowy Studio began as a passion project, blending modern design with the beauty of global craftsmanship. Inspired by a commitment to sustainability and cultural storytelling, we create timeless, luxurious garments that celebrate heritage while embracing innovation. From handwoven fabrics to eco-friendly processes, every piece we design tells a story of artistry, purpose, and care. Our mission is to empower artisans, preserve traditional techniques, and redefine luxury through conscious fashion.

Dedicated to empowering women, Fioletowy transforms lives through creativity and dignity. 2024 has been a year of breakthrough for the brand presenting during Milan Fashion Week, New York Fashion Week, and Times Fashion Show in India.

In doing so, the brand has gained features in magazines like Harper’s Bazaar, Vogue Runway, Elle, and other prestigious publications.

At Art Basel Miami, Fioletowy unveiled their “Heritage Reimagined” capsule collection, a celebration of cultural fusion featuring intricate embroidery, sustainable fabrics, and bold silhouettes inspired by global artistry. The showcase earned praise for its innovative craftsmanship and resonated with an audience that values purpose-driven design. Looking ahead, Fioletowy Studio is expanding its reaches and digital experiences while deepening our commitment to sustainability and artisan empowerment. Their vision is to inspire a global movement for mindful, meaningful fashion. Ending this year with Art Basel Miami, Fioletowy is so honored to present during such a prestigious event. Our goals for the next few years are to continue building the brand with new innovations!

Samatha Chandrashekar

www.fioletowystudio.com

fioletowydesigns@gmail.com

IG: @fioletowystudio

+91 9916757610

Rajeev Fernando

Dr. Rajeev Fernando is an internationally renowned humanitarian and Infectious Diseases Doctor. His up and coming ethical brand has in three short months moved briskly in the ranks.

During this period he has done shows during New York Fashion Week, Paris Fashion Week, and Los Angeles Fashion Week.

During Art Basel Miami, he bridges art and fashion in a creative short film evoking his humanitarian work while showcasing his clothing collection. Nonetheless, Fernando’s altruism crossing over into the fashion world is the true art. His Humanitarian Leather Jackets provide medical funding to areas suffering from conflicts and gender-based injustices. Having traveled to approximately 60 countries, he gets inspiration from the streets of Brooklyn, Barcelona, and Tokyo for his genuine and crocodile leather collection. He fuses Indian sari blouses with western bottoms. Fernando runs a tight schedule working as a physician, fashion designer, and documentary filmmaker. Stay tuned to this designer as his fusion of art, fashion and humanitarianism is ready for the world.

Rajeev Fernando

https://www.rf-apparel.com/

rajeevsantiago@gmail.com

IG: @rajeevfernandomd

+1 (267)664-0347

THE VENUE

The Mondrian South Beach

Known for its groundbreaking design and panoramic views of Miami’s Biscayne Bay, Mondrian South Beach is a “must-see” destination. Upon entering the iconic hotel, guests are welcomed into a spacious lobby with a lounge and bar featuring intricately crafted cocktails and awe-inspiring bayfront views. The elevated look and feel makes way into the guest rooms with a relaxed elegance of fresh and simple design. Easily transform from day to night with an evolving escalating energy, mood, and dynamic vibe at Baia Beach Club. Inspired by the bohemian energy, casual chic, and welcoming multi-cultural spirit of the Mediterranean, Baia Beach Club evokes the laid-back sophistication of international coastal living and offers a spa, restaurant, bar, and lounge.

MONDRIAN SOUTH BEACH

Reservations here or call 305-514-1500

For more information or on this event questions please contact Karine Charlemagne at agent@chezlesmannequins.com | IG:@chezlesmannequins | www.chezlesmannequins.com

Production: Chez Les Mannequins @chezlesmannequins

Artists: @amarildoruci @lovecashionista

Brands: @fioletowystudio @amarildoshop @lovecashionista @rajeevfernando

Venue: Mondrian South Beach @mondrianhotelsobe

Photography: Karine Charlemagne @k.c.picto_films and Briana Lee @lovecashionista

Media Contact
Company Name: Chez Les Mannequins
Contact Person: Karine Charlemagne
Email: Send Email
City: Pembroke Pines
State: Florida
Country: United States
Website: https://www.chezlesmannequins.com/

Samuel Chua’s “Zero to App Store Hero” Achieves Amazon Bestseller Status, Empowering Aspiring “Appreneurs” to Launch and Scale Sustainable App Businesses

Now an Amazon bestseller, “Zero to App Store Hero” by Samuel Chua provides aspiring appreneurs with a step-by-step roadmap into the booming global app industry, projected to top $935 billion in revenue.

The evolving world of app entrepreneurship isn’t just for developers anymore. In Zero to App Store Hero: A Beginner’s Blueprint for Launching & Scaling Apps, Samuel Chua debunks the myth that you need technical expertise to succeed. Instead, he offers a straightforward path for the next wave of “appreneurs” — visionary entrepreneurs who see apps as a vehicle for innovation, impact, and profit.

Chua leverages insights from building over 70 successful apps, presenting a proven approach that simplifies the journey from concept to sustainable growth. At the core is the 4D Strategy, a user-friendly framework that breaks app creation and scaling into four actionable phases:

Discover: Use the IMAGINE framework to validate market demand, identify user needs, and confirm revenue potential before investing significant time or money.
Design: Map customer journeys, streamline interfaces, and craft intuitive user experiences that keep people engaged and coming back.
Develop: Transform your validated idea into a tangible product—whether coding or going no-code—ensuring it’s scalable, sustainable, and ready for the competitive marketplace.
Deliver: Launch strategically, employ targeted marketing tactics, and integrate user feedback loops to fuel ongoing improvement and long-term success.

“Building a profitable app isn’t just for developers; it’s for appreneurs who recognize the untapped potential around them,” says Chua. “Zero to App Store Hero shows that with the right guidance, anyone can turn an idea into a meaningful, enduring digital asset.”

Early readers commend the book’s hands-on practicality. One reviewer writes, “Samuel’s 4D Strategy removes the guesswork and makes the entire process accessible. It’s a must-read for any aspiring entrepreneurs.”

As apps continue to reshape sectors like healthcare, education, and finance, Zero to App Store Hero highlights the need for solutions that go beyond short-term gains. Chua’s roadmap encourages appreneurs to focus on delivering genuine user value, embracing sustainable practices, and building assets designed to thrive in the rapidly changing digital landscape.

About Samuel Chua

Samuel Chua is the founder of Coconut Lab, a Singapore-based studio specializing in custom app development and software solutions. Having shared stages with renowned thought leaders like Robert Kiyosaki and T. Harv Eker, Chua couples entrepreneurial insight with a passion for empowering the next generation of appreneurs. His bestselling book, Zero to App Store Hero, is available now on Amazon.

For more information, visit www.coconutlab.io.

Media Contact
Company Name: Next Level Academy
Contact Person: Samuel Chua
Email: Send Email
Phone: +6597719422
Address:10 Anson Rd, #18-13 International Plaza
State: Singapore 079903
Country: Singapore
Website: https://nextlevelacademy.io

Intrahepatic Cholangiocarcinoma Pipeline Insights 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Intrahepatic Cholangiocarcinoma pipeline constitutes 20+ key companies continuously working towards developing 20+ Intrahepatic Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Intrahepatic Cholangiocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Intrahepatic Cholangiocarcinoma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Intrahepatic Cholangiocarcinoma Market.

Some of the key takeaways from the Intrahepatic Cholangiocarcinoma Pipeline Report:

Companies across the globe are diligently working toward developing novel Intrahepatic Cholangiocarcinoma treatment therapies with a considerable amount of success over the years. Intrahepatic Cholangiocarcinoma Key players such as – Xencor, Inc., Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics, Inc., TriSalus Life Sciences, Jiangsu HengRui Medicine Co., Ltd., Virogin Biotech Ltd., Basilea Pharmaceuticals, and others, are developing therapies for the Intrahepatic Cholangiocarcinoma treatment

Intrahepatic Cholangiocarcinoma Emerging therapies such as – XmAb®22841, RLY-4008, KIN-3248, FT-2102, SD 101, Camrelizumab, VG161, Derazantinib, and others are expected to have a significant impact on the Intrahepatic Cholangiocarcinoma market in the coming years.
In January 2024, Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company specializing in advanced personalized MRD technology (Haystack MRD™), has partnered with TriSalus Life Sciences for a research collaboration. This initiative aims to assess therapeutic responses and gather molecular insights during the clinical development of TriSalus’ SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist. SD-101 is administered through hepatic arterial infusion or pancreatic retrograde venous infusion in Phase 1 and 1b trials using TriSalus’ proprietary Pressure-Enabled Drug Delivery™ (PEDD™) system, designed to address intratumoral pressure challenges in patients with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma.

Intrahepatic Cholangiocarcinoma Overview

Intrahepatic cholangiocarcinoma (ICC) is a type of cancer that originates in the cells within the bile ducts inside the liver.

Get a Free Sample PDF Report to know more about Intrahepatic Cholangiocarcinoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-pipeline-insight

Route of Administration

Intrahepatic Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Molecule Type

Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Intrahepatic Cholangiocarcinoma Pipeline Therapeutics Assessment

Intrahepatic Cholangiocarcinoma Assessment by Product Type
Intrahepatic Cholangiocarcinoma By Stage and Product Type
Intrahepatic Cholangiocarcinoma Assessment by Route of Administration
Intrahepatic Cholangiocarcinoma By Stage and Route of Administration
Intrahepatic Cholangiocarcinoma Assessment by Molecule Type
Intrahepatic Cholangiocarcinoma by Stage and Molecule Type

DelveInsight’s Intrahepatic Cholangiocarcinoma Report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Some of the key companies in the Intrahepatic Cholangiocarcinoma Therapeutics Market include:

Key companies developing therapies for the Intrahepatic Cholangiocarcinoma are – Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bayer, Loxo Oncology, QED Therapeutics, Janssen Pharmaceutical, Taiho Oncology, RedHill Biopharma, GlaxoSmithKline, Merck, Eisai, Taiho Pharmaceutical, Sorrento Therapeutics, Yuhan Corporation, Hutchison Medipharma, Jiangsu HengRui Medicine, AstraZeneca, Eli Lilly, Servier Laboratories, Genoscience Pharma, Forma Therapeutics, Array BioPharma, and others

Download Sample PDF Report to know more about Intrahepatic Cholangiocarcinoma drugs and therapies

Emerging Intrahepatic Cholangiocarcinoma Drugs Under Different Phases of Clinical Development Include:

XmAb®22841: Xencor, Inc.
RLY-4008: Relay Therapeutics
KIN-3248: Kinnate Biopharma
FT-2102: Forma Therapeutics, Inc.
SD 101: TriSalus Life Sciences
Camrelizumab: Jiangsu HengRui Medicine Co., Ltd.
VG161: Virogin Biotech Ltd
Derazantinib: Basilea Pharmaceuticals

Intrahepatic Cholangiocarcinoma Pipeline Analysis:

The Intrahepatic Cholangiocarcinoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Intrahepatic Cholangiocarcinoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Intrahepatic Cholangiocarcinoma Treatment.
Intrahepatic Cholangiocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Intrahepatic Cholangiocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Intrahepatic Cholangiocarcinoma market.

Further Intrahepatic Cholangiocarcinoma product details are provided in the report. Download the Intrahepatic Cholangiocarcinoma pipeline report to learn more about the emerging Intrahepatic Cholangiocarcinoma therapies

Intrahepatic Cholangiocarcinoma Pipeline Market Drivers

Rising incidence of Cholangiocarcinoma. ICC makes up 8–10% of all Cholangiocarcinoma
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma Pipeline Market Barriers

Poor prognosis and diagnosis of the disease
Difficulty in developing novel therapies. Drugs may lose effectiveness after several months as the tumor may become resistant to the medication.

Scope of Intrahepatic Cholangiocarcinoma Pipeline Drug Insight

Coverage: Global
Key Intrahepatic Cholangiocarcinoma Companies: Xencor, Inc., Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics, Inc., TriSalus Life Sciences, Jiangsu HengRui Medicine Co., Ltd., Virogin Biotech Ltd., Basilea Pharmaceuticals, and others
Key Intrahepatic Cholangiocarcinoma Therapies: XmAb®22841, RLY-4008, KIN-3248, FT-2102, SD 101, Camrelizumab, VG161, Derazantinib, and others
Intrahepatic Cholangiocarcinoma Therapeutic Assessment: Intrahepatic Cholangiocarcinoma current marketed and Intrahepatic Cholangiocarcinoma emerging therapies
Intrahepatic Cholangiocarcinoma Market Dynamics: Intrahepatic Cholangiocarcinoma market drivers and Intrahepatic Cholangiocarcinoma market barriers

Request for Sample PDF Report for Intrahepatic Cholangiocarcinoma Pipeline Assessment and clinical trials

Table of Contents

1 Intrahepatic Cholangiocarcinoma Report Introduction

2 Intrahepatic Cholangiocarcinoma Executive Summary

3 Intrahepatic Cholangiocarcinoma Overview

4 Intrahepatic Cholangiocarcinoma- Analytical Perspective In-depth Commercial Assessment

5 Intrahepatic Cholangiocarcinoma Pipeline Therapeutics

6 Intrahepatic Cholangiocarcinoma Late Stage Products (Phase II/III)

7 Intrahepatic Cholangiocarcinoma Mid Stage Products (Phase II)

8 Intrahepatic Cholangiocarcinoma Early Stage Products (Phase I)

9 Intrahepatic Cholangiocarcinoma Preclinical Stage Products

10 Intrahepatic Cholangiocarcinoma Therapeutics Assessment

11 Intrahepatic Cholangiocarcinoma Inactive Products

12 Company-University Collaborations (Licensing/Partnering) Analysis

13 Intrahepatic Cholangiocarcinoma Key Companies

14 Intrahepatic Cholangiocarcinoma Key Products

15 Intrahepatic Cholangiocarcinoma Unmet Needs

16 Intrahepatic Cholangiocarcinoma Market Drivers and Barriers

17 Intrahepatic Cholangiocarcinoma Future Perspectives and Conclusion

18 Intrahepatic Cholangiocarcinoma Analyst Views

19 Appendix

20 About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Intrahepatic Cholangiocarcinoma Pipeline Insights 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics

Shen Feng Yong’s Pirate King Branding Achieves Amazon Bestseller Status, Empowering Businesses to Defy Traditional Branding Norms

Shen Feng Yong’s latest book, Pirate King Branding, has become an Amazon bestseller, offering businesses strategies to disrupt competitive markets and build standout brands in the digital age.

Pirate King Branding: Break the Rules, Disrupt the Market & Become the #1 Choice, authored by branding strategist and Digital X Branding founder Shen Feng Yong, has climbed to Amazon’s bestseller list, captivating business leaders worldwide with its innovative approach to brand differentiation. Known as “The Branding Pirate,” Shen draws on over nine years of experience and more than 200 projects with leading brands such as Signature Market to deliver a framework that guides brands in defying conventional strategies and cultivating unique identities that resonate deeply with consumers.

In a market where 81% of consumers say they need to trust a brand before making a purchase, Pirate King Branding provides a roadmap for businesses to transcend price and quality battles and forge customer-centric narratives that foster loyalty and distinction. Shen’s philosophy of “different is better than better” speaks to a growing need for authenticity, a quality that 86% of consumers value when choosing brands, particularly in sectors facing rapid shifts, such as AI, trading, and e-commerce.

“Today’s brands need more than features and discounts to win over customers,” Shen Feng Yong says. “They need a narrative that resonates on a personal level, giving audiences a genuine reason to choose them over others. Pirate King Branding is about inspiring companies to break traditional molds and embrace bold strategies that highlight their authentic strengths and values.”

In the book, Shen introduces a four-step process designed to help businesses make a lasting impact. His framework begins with:

Brand Discovery – Understanding the “Perfect Buyer Persona” (PBP), aligning messaging, and uncovering unique customer insights.

Brand Differentiation – Developing positioning that isn’t just about being “better” but about being memorable and relevant.

Brand Experience – Consistently delivering brand values across customer interactions to build trust and loyalty.

Brand Evolution – Adapting and expanding through co-creation and strategic partnerships to ensure longevity and relevance.

The book’s insights cater not only to entrepreneurs and startups but also to established companies navigating today’s fast-paced digital economy. With 90% of consumers expecting consistent experiences across all channels, Shen’s approach provides a sustainable model for creating genuine connections, which modern consumers demand in their brand interactions.

Shen Feng Yong’s journey into branding began as a car sales advisor, where he saw firsthand how customers prioritize brand reputation over product features or discounts. Over the years, his work has continued to shape industries, inspiring brands to create identities that captivate audiences and establish loyalty. His long-term goal is to help businesses secure loyal customers and become market leaders with compelling, differentiated brand narratives.

Pirate King Branding is available now on Amazon, resonating with readers eager to learn from Shen’s expertise and embrace strategies to thrive in competitive markets. For additional information on Shen Feng Yong and his work, visit Digital X Branding.

About Shen Feng Yong

Shen Feng Yong, also known as “The Branding Pirate,” is the founder of Digital X Branding, a Malaysian-based agency specializing in brand differentiation strategies. With over nine years of experience, Shen has guided more than 200 successful projects, helping companies transcend traditional competition metrics to become unique, customer-focused brands. His mission is to inspire brands to become irreplaceable by fostering genuine connections with their audiences.

Sabrina Princessa Wang, a Singaporean entrepreneur and Amazon bestselling author, has enthralled people all over with her new book, The Lazy Person’s Guide to Success

Amazon bestselling author Sabrina ‘Princessa’ Wang is shaking up the world of success and entrepreneurship with her latest book, The Lazy Person’s Guide to Success. Known for her groundbreaking work in artificial intelligence, automation, and women’s empowerment, Sabrina delivers a refreshing perspective for ambitious dreamers seeking balance, joy, and achievement.

Dubbed the “Princess of AI, Automation, Tech, and Entrepreneurship“, as a speaker at Nas Summit, Sabrina started her entrepreneurial journey at just 15 with her first apparel business. Fast forward to today, she’s the powerhouse behind multiple thriving ventures, including People’s Inc. 360, Royal Privileged, and the Royal Visionary Society. Through these platforms, Sabrina combines cutting-edge technology with purpose, empowering thousands to dream big, work smart, and live better.

Her new book, The Lazy Person’s Guide to Success, turns the “hustle harder” narrative on its head, offering an alternative rooted in well-being, productivity, and sustainability. Topping Amazon charts in five categories like Organisational Behaviour, Strategic Management, and Business Systems, the book resonates with professionals worldwide, many of whom are seeking reprieve from burnout.

“Success shouldn’t mean sacrificing yourself along the way,” Sabrina explains. “This book is my personal guide to building businesses without burning out – and finding happiness in the process.” Drawing from her own experiences managing multiple companies and recovering from burnout, Sabrina presents a deeply personal and pragmatic roadmap for achieving success on your own terms.

At the heart of Sabrina’s technological edge is Seraphina, her AI-powered digital twin, which plays a pivotal role in streamlining processes and enhancing efficiency in her ventures. “Seraphina represents how AI and automation can free up time, enabling entrepreneurs to focus on creativity, strategy, and the things that truly matter,” Sabrina shares. This same philosophy powers her marketing automation platform, People’s Inc. 360, which simplifies and democratises powerful solutions for entrepreneurs worldwide.

The book openly shares insights from her life, including the challenges of juggling personal relationships with professional growth. It also highlights her dedication to mentoring women through the Royal Launch School, originally part of PRINCESSA Academy, now rebranded as the Royal Visionary Society. This evolution reflects Sabrina’s commitment to expanding her vision and creating a stronger, more inclusive platform for aspiring entrepreneurs.

While the book’s release preceded one of her most significant personal challenges – her divorce – Sabrina reflects on how the end of her marriage taught her invaluable lessons about resilience, balance, and the importance of honouring well-being. She credits her ex-husband for being a steadfast source of support during their time together, particularly as she built People’s Inc. 360, a cornerstone of her entrepreneurial journey.

These reflections now fuel Sabrina’s mission to make life smoother for entrepreneurs. Through the Royal Visionary Society, she strives to be a pillar of support for others, providing tools, mentorship, and encouragement to turn passion into profit. Similarly, with People’s Inc. 360, her marketing automation platform, she simplifies and democratises powerful solutions, making it easier and more affordable for entrepreneurs to focus on what truly matters – creating a balanced and fulfilling life.

Her timing couldn’t be better. With nearly 60% of professionals reporting burnout, The Lazy Person’s Guide to Success arrives as a beacon of hope, offering readers actionable techniques to streamline their lives, focus on what truly matters, and achieve their dreams with energy and ease.

Sabrina’s career is a story of restlessness, reinvention, and relentless innovation. She’s transformed industries with ventures like People’s Inc. 360, an AI-driven marketing automation platform, and Royal Privileged, an investment house and brand builder crafting products that empower women and modern consumers alike.

Her passion for empowerment extends beyond business. At the Royal Visionary Society’s Royal Launch School, Sabrina mentors women (sometimes men), arming them with tools to turn their passions into thriving businesses. Her book builds on this mission, bringing her insights to a global audience ready to rewrite the rules of success.

For Sabrina, the success of her book represents more than a personal milestone – it’s a movement. Alongside accolades like being named one of The Silicon Review’s “30 Entrepreneurs of the Year” and winning the Singapore SME 500 and Spirit of Enterprise Awards, Sabrina is solidifying her legacy as a champion for innovation, empowerment, and balanced living.

Now available on Amazon, The Lazy Person’s Guide to Success invites readers from all walks of life to explore a new definition of success – one where ambition and well-being go hand in hand.

About Sabrina ‘Princessa’ Wang

Sabrina ‘Princessa’ Wang is an Amazon bestselling author, visionary entrepreneur, and founder of People’s Inc. 360, Royal Privileged, and the Royal Visionary Society’s Royal Launch School. A trailblazer in AI, automation, tech, entrepreneurship and women’s empowerment, Sabrina has been featured in The Straits Times, Vulcan Post, and more. Through her ventures, she empowers communities with tech-driven solutions and a fresh approach to success. Based in Singapore, she continues to inspire through her groundbreaking work and writing.

Visit Sabrina’s official website at www.princessadiary.com and subscribe to her Royal Confessions newsletter to learn more.

Media Contact
Company Name: Next Level Academy
Contact Person: Shen Feng Yong
Email: Send Email
Phone: +6597719422
Address:10 Anson Rd, #18-13 International Plaza
State: Singapore 079903
Country: Singapore
Website: https://nextlevelacademy.io

BlackBox Startup Law Celebrates 10th Anniversary with California Office Expansion

San Francisco, CA – December 20, 2024 – BlackBox Startup Law, a specialized legal service provider for startups in Latin America, proudly celebrates its 10th anniversary by opening a new office in San Francisco, California. This expansion underscores the firm’s commitment to bridging the gap between Latin America’s growing startup ecosystem and the venture capital opportunities in Silicon Valley.

Victor Aguirre and Ricardo Weder (Founder of Jüsto)

“We are celebrating a decade of empowering Latin American founders with the legal expertise they need. Expanding to California allows us to strengthen ties with the global venture capital ecosystem and better serve startups looking to scale internationally,” said BlackBox Startup Law Co-Founder Victor Aguirre.

Founded a decade ago by Victor Aguirre and Carlos Aguerrebere, BlackBox Startup Law was established to address a significant gap in legal services for early-stage companies and investors in Latin America. Since then, the business has expanded from a partnership of two people to a full-service enterprise with more than 60 specialists. More than 100 businesses have benefited from BlackBox’s assistance over the years, and the company has been instrumental in organizing profitable investment rounds and fostering regional expansion.

BlackBox Startup Law’s California office is strategically positioned to support Latin American founders operating remotely from the U.S. By offering tailored legal solutions for cross-border challenges, the firm ensures startups comply with regional regulations, structure their fundraising efforts effectively, and optimize international tax strategies.

“We ensure startups optimize their operations while fulfilling local compliance requirements in every jurisdiction they operate in. This includes structuring entities to facilitate fundraising, managing regulatory obligations, and addressing tax efficiencies across Latin America and the U.S.,” Aguirre explained.

The firm’s track record includes advising Jüsto, Mexico’s first digital supermarket, on its record-breaking $65 million Series A investment—the largest of its kind in Latin America—as well as a $20 million credit line from HSBC. Other notable clients include fintech leader Jeeves, ride-hailing platform Cabify, and logistics giant Lalamove, highlighting BlackBox’s role as a trusted partner within the Latin American startup ecosystem.

“San Francisco was a natural choice for our expansion,” added Carlos Aguerrebere, Co-Founder of BlackBox Startup Law. “The city is a global hub for innovation and venture capital, and it aligns with our vision of supporting Latin American founders as they navigate the complexities of scaling internationally.”

The Founder-First Approach

BlackBox Startup Law distinguishes itself through a deeply ingrained founder-first philosophy. Recognizing the distinct hurdles faced by those building businesses in Latin America, the firm leverages its intimate understanding of the region’s complex web of treaties, regulations, tax codes, and policies. This empathetic approach translates into bespoke solutions, delivered with agility, empowering founders to confidently launch and scale their ventures across the diverse Latin American landscape.

Bespoke Solutions Tailored to Unique Needs

BlackBox doesn’t offer a one-size-fits-all solution. The company recognizes that each startup is unique, with its own set of circumstances, founders’ residency, and personal legal and tax obligations. BlackBox provides bespoke, tailored advice that takes these factors into account, ensuring every client receives the most effective and personalized support possible.

Navigating the Evolving Venture Capital Landscape

A key trend shaping the Latin American startup ecosystem is the shift toward U.S. holding companies over traditional Cayman Sandwich structures. Driven by evolving tax policies and the U.S.’ robust legal framework, startups and investors are increasingly recognizing the benefits of U.S. structures, including lower tax rates and greater access to capital. BlackBox stays ahead of these changes by continuously updating its knowledge and adapting its strategies to best serve its clients.

To strengthen ties with the Hispanic community and assist creators across the Americas, BlackBox Startup Law intends to grow its business even more in the future, with Miami as its next destination.

To learn more about BlackBox Startup Law’s services and how they can help startups streamline fundraising and achieve sustainable growth, visit www.blackboxmx.com or connect with the firm on LinkedIn at BlackBoxLaw.

BlackBox Startup Law

About BlackBox Startup Law

BlackBox Startup Law is a leading legal service provider specializing in venture capital, fundraising, and regulatory compliance for startups in Latin America. With ten years of experience, BlackBox provides customized, founder-first solutions to assist startups in navigating intricate legal environments, obtaining capital, and growing their businesses. With its headquarters in Latin America and a recently expanded office in San Francisco, BlackBox serves as a bridge between the LatAm and global startup ecosystems and has played a key role in more than 100 successful startup launches, including Jüsto’s record-breaking $65 million Series A.

Media Contact
Company Name: BlackBox Startup Law
Contact Person: Victor Aguirre
Email: Send Email
Country: United States
Website: https://www.blackboxmx.com/